AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00036868 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Study NCT00036868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMF regimen
Study NCT00036868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00036868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00036868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT03779776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin AD
Description: In Vitamin AD group, the very preterm infants will receive the daily vitamin AD with vitamin A at 1500 IU/day and vitamin D at 500 IU/day in drop form added to their enteral feeds when minimal feeding is introduced, and continue to 28 days or discharge. In this group ,the patient also will receive standard intravenous multivitamin preparation (1 ml/kg/d,containing VA 230 IU/kg/d, VD 80 IU/kg/d) within daily on parenteral nutrition until fed 120ml/kg.
Study NCT03779776 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: In this group ,the patient will only receive standard intravenous multivitamin preparation (1 ml/kg/d,containing VA 230 IU/kg/d, VD 80 IU/kg/d) within daily on parenteral nutrition until fed 120ml/kg.
Study NCT00894621 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01726582 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Milestone 2: Chemoradiotherapy (cXRT)
Description: A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or intensity-modulated radiation therapy (IMRT) techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
Study NCT01726582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milestone 3: Targeted chemotherapy prior to surgery
Description: The molecular profile from the biopsy before surgery will point to a particular chemotherapy treatment.
Study NCT01726582 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Milestone 3: Chemoradiotherapy (cXRT)
Description: A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
Study NCT01726582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milestone 4: standard FOLFIRINOX chemotherapy prior to surgery
Description: A biopsy of the borderline tumor does not provide a molecular profile that can be used to target treatment. The treatment will be standard FOLFIRINOX chemotherapy regimen.
Study NCT03258411 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rapid Expansion of palatal suture
Study NCT01138709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitala
Description: Vitala™ Continence Control Device
Study NCT01726582 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Milestone 4: Chemoradiotherapy (cXRT)
Description: A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
Study NCT02501616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT02501616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Study NCT01704482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: NAC bolus of 150 mg/kg in 250 mL of 5% glucose over 15 mins, followed by continuous intravenous infusion of 50 mg/kg in 250 mL of 5% glucose over 4 hrs, then 100 mg/kg in 1000 ml of 5% glucose over 20 hrs
Study NCT04512664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cold application
Description: cold application with gel pacs
Study NCT04512664 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cold application
Description: cold application with gel pacs
Study NCT00324987 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT00324987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Given PO
Study NCT00324987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib Mesylate
Description: Given PO
Study NCT00324987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01704482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00494572 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sterile water
Description: sterile water
Study NCT04150224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169 640 mg OD
Description: Two administrations once a day with a wash-out period: food effect
Study NCT04150224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169 640 mg BiD
Description: Twice a day fasted; 1 day of administration
Study NCT04150224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169 960 mg SD
Description: Once a day fasted
Study NCT02299011 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orsiro drug eluting stent
Description: Orsiro Hybrid drug eluting stent
Study NCT02299011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biomatrix drug eluting stent
Description: Biomatrix Flex drug eluting stent
Study NCT04277273 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Questionnaires WHOQOL-BREF and GOHAI
Study NCT03056170 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: real tDCS
Description: In active stimulation, the Transcranial Direct Current Stimulation device will produce a direct current of 1 mA from one electrode to the other for 30 min with a ramp up at the beginning and a ramp down at the end of the stimulation of 30 s. The sham or active mode is chosen by a numeric code.
Study NCT03056170 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: real tDCS
Description: In active stimulation, the Transcranial Direct Current Stimulation device will produce a direct current of 1 mA from one electrode to the other for 30 min with a ramp up at the beginning and a ramp down at the end of the stimulation of 30 s. The sham or active mode is chosen by a numeric code.
Study NCT03839355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Dosage either 5mg or 2.5mg for 2 years
Study NCT03839355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Dosage assessed by your treating physician for 2 years
Study NCT01840124 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation of fibroids
Description: The Acessa device delivers radiofrequency energy to uterine fibroids to destroy fibroid tissue. The patient undergoes a standard laparoscopy of the pelvis. A laparoscopic ultrasound is performed to identify the precise size and location of the fibroids. The Acessa radiofrequency probe is then placed into the fibroid and the radiofrequency energy is delivered. The fibroid tissue is destroyed and the fibroid shrinks down in size to decrease fibroid-related symptoms.
Study NCT02033343 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prostate cancer radiotherapy using real-time tracking
Description: Radiotherapy delivered using Calypso radiofrequency emitting beacon guided real-time prostate localisation and beam adjustment using Dynamic Multi-leaf Collimator tracking software.
Study NCT00084825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 30 mg/m\^2 IV on days 1, 8, 15, and 22 every 42 days
Study NCT00084825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Description: 600 mg orally daily
Study NCT01995253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Energy expenditure estimation in controlled conditions
Description: Volunteers were asked to perform several activities such as walking at different paces, running, sitting, standing still or taking public transportation for about 3h30 They wore 2 research sensors that estimate energy expenditure: Armband and Actiheart. They also wore a smartphone (in a front pant pocket) that collected accelerometry data.
Study NCT01995253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Energy expenditure estimation in free-living conditions
Description: Volunteers were asked to wear sensors during about 12 hours, one day. They wore 2 research sensors that estimate energy expenditure: Armband and Actiheart. They also wore a smartphone (in a front pant pocket) that collected accelerometry data.
Study NCT02475109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAN-90806 Ophthalmic Solution
Study NCT00855634 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resection of metastases
Description: resection of the primary tumor, followed by resection of the liver metastasis/metastases
Study NCT00855634 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resection of infiltrated veins
Description: resection of the primary tumor with resection of the portal vein (and/or superior mesenteric vein/splenic
Study NCT01773434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORAb-004
Description: MORAb-004 5 mg/mL is administered as an intravenous infusion (IV) in an escalating dose design and will not be escalated or de-escalated in individual participants.~Part 1 (Dose escalation): 4 weekly administrations of 2, 4, 8, and 12 mg/kg in four different cohorts on Days 1, 8, 15, and 22 of a 4-week cycle (28 days).~Part 2 (Cohort expansion): 4 and 8 mg/kg on Days 1, 8, 15, and 22 of a 4-week cycle (28 days) and 12 mg/kg biweekly administration on Days 1 and 15 of a 4-week cycle in different cohorts. The dosages in Part 2 can be amended considering the results of Part 1.
Study NCT01813682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment group1
Description: fe-1 group with TPN of iron supplementation of 200μg/kg/d.
Study NCT01813682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment group2
Description: fe-2 group with TPN of iron supplementation of 400μg/BW (BW=birth weight)
Study NCT02652676 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reversible Pulmonary Artery Banding
Description: A sternotomy incision is used for application of the rPAB. Tightening is under echocardiographic control until the inter-ventricular septum becomes a midline structure. Myocardial function is augmented with inotropic and vasodilator agents that are weaned after 2-4 weeks. The infant is separated from mechanical ventilation within the first week, and enteric feeding is resumed. The infant is discharged on oral medications, with follow-ups. Band enlargement is in stages as a balloon catheter-based procedure if a finding of increasing right ventricular dilation, onset or worsening tricuspid valve regurgitation, or a gradual late increase in plasma B-type natriuretic peptide (BNP) levels, opting for a mild residual right ventricle-main pulmonary artery pressure gradient of 15-30 mmHg.
Study NCT02652676 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GORE-TEX DualMesh EMERGE PLUS Biomaterial
Description: The study is being conducted to evaluate the procedure, not the materials being used. The study uses the patch as materials to create the band around the pulmonary artery which is currently done routinely off label. The patch is approved as a cardiovascular patch. FDA 501(k) K032168.
Study NCT04063748 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audiological rehabilitation
Description: Experimental: tablet-based take-home auditory-cognitive training, which consists of phoneme tasks, words in quiet and in different types of noise
Study NCT04063748 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Placebo Rehabilitation
Description: CI-users: Placebo, tablet-based take-home psychophysical tasks, reading (non auditory)
Study NCT04063748 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Passive Control
Description: No intervention in the passive control group for HA-users.
Study NCT03378024 — intervention group
Intervention type: DEVICE
Intervention: oscillometric (Omron Colin co)
Description: fast measurements of the brachial-ankle pulse wave velocity (baPWV) and the resting ankle-brachial index(ABI) with the oscillometric method (Omron Colin co, Japan)
Study NCT01164631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioajusta X Orthodontic treatment
Description: Oral Appliance that promotes semi-rapid maxillary expansion, while corrects tongue positioning and jaws relationship
Study NCT01297738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal size increase with HFHS
Description: On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a high-fat, high-sugar liquid medical food supplement (Nutridrink®). Subjects consume the Nutridrink® with their meals, which results in an increase in meal size.
Study NCT00324987 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00324987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00324987 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01726582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milestone 5: Targeted chemotherapy after surgery
Description: The molecular profile from the surgical specimen will point to a particular chemotherapy treatment.
Study NCT01726582 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Milestone 5: Chemoradiotherapy (cXRT)
Description: A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
Study NCT01726582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milestone 6: Gemcitabine after surgery
Description: Chemotherapy treatment with Gemcitabine.
Study NCT01726582 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Milestone 6: Chemoradiotherapy (cXRT)
Description: A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
Study NCT01726582 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Milestone 7: Chemoradiotherapy (cXRT)
Description: A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
Study NCT01726582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milestone 8: Targeted chemotherapy after surgery
Description: The molecular profile from the surgical specimen will point to a particular chemotherapy treatment.
Study NCT01726582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milestone 9: Gemcitabine after surgery
Description: Chemotherapy treatment with Gemcitabine.
Study NCT01726582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milestone 10: No additional therapy after surgery
Description: The molecular profile of the tumor that was removed during surgery points to a lack of treatment affect for available therapies. No additional therapy is recommended.
Study NCT00241345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Study NCT00241345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Study NCT04150224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169 1280 mg SD
Description: Once a day fasted
Study NCT04150224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169 1280 mg MD
Description: Once a day after meal, 14 doses
Study NCT01617603 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cocoa Polyphenols
Description: 20g/d of product, two active products provide 20 mg/d epicatechin, on visiting occasions, an acute dose of 40g product to be given
Study NCT01617603 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cocoa Polyphenols
Description: 20g/d of product, two active products provide 20 mg/d epicatechin, on visiting occasions, an acute dose of 40g product to be given
Study NCT01617603 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa Polyphenols
Description: 20g/d of product, two active products provide 20 mg/d epicatechin, on visiting occasions, an acute dose of 40g product to be given
Study NCT03750981 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 12 week pilot intervention study.
Description: Participants will begin a 12-week high-intensity functional training program conducted at CrossFit® in the D, located in downtown Detroit, Northville Athletix in Northville and Five Lakes CrossFit® in Farmington Hills.
Study NCT03771833 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MARIA scan
Description: The MARIA breast imaging system comprises of a scanning unit, housed under a patient bed. The scanning unit houses a hemispherical array, into which varying sizes of insert are fitted to ensure a close fit to the breast. The patient lies prone on the bed with their breast pendulous through an aperture in the bed and the scanning unit is risen to meet the breast. The fit is non-compressing and the scanner does not use ionising radiation.
Study NCT00832351 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mobilisation
Description: Mobilisation
Study NCT00064246 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT00064246 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: indium In 111 ibritumomab tiuxetan
Description: Given IV
Study NCT00064246 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan
Description: Given IV
Study NCT04213898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210+Albumin-bound paclitaxel + epirubicin
Description: Neoadjuvant therapy：SHR-1210, 200mg,iv, q3w, for 6 cycles; Albumin-bound paclitaxel: 125 mg/m2, iv, d1, d8, and d15, 21 days as a cycle, for 6 cycles; Epirubicin: 75mg / m2, iv, d1, 21 days as a cycle, for 6 cycles; The surgery was performed 3-4 weeks after the completion of neoadjuvant chemotherapy.
Study NCT02134457 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ranibizumab
Study NCT00874068 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: InFat™ based infant formula
Description: high sn-2 palmitic acid oil based infant formula
Study NCT00874068 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard vegetable oil based infant formula
Description: standard vegetable oil based infant formula
Study NCT03732066 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Text Messages
Description: Usual text messages four times a week, including cardiovascular knowledge and follow-up reminders, such as risk factors for CHD and typical symptoms of myocardial infarction.
Study NCT03732066 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Text Messages
Description: Usual text messages four times a week, including cardiovascular knowledge and follow-up reminders, such as risk factors for CHD and typical symptoms of myocardial infarction.
Study NCT03732066 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Reminders
Description: 1. The mHealth tools will provide special interventions according to the patients' medical history. For example, patients with hypertension will receive daily reminders on blood pressure measurement and medication. They will also receive early warning on hypertension with a systolic blood pressure of >180 mmHg or \<90 mmHg. Patients who smoke will be required to quit smoking. Every patient will receive a Health Report monthly, which will reflect their drug compliance, blood pressure and so on.~2. Drug Reminders: Patients' medication information will be recorded by obtaining pictures of their medication. Patients will be asked to punch time clocks simply in the mHealth tools. If they forget to punch cards, they can punch cards whenever they think of it. If there is no record of medication for 3 days, SMS alerts will be received, and phone calls will be received over 7 days.
Study NCT03732066 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Responses
Description: 1. Auto-Response: After sending personal or discomfort symptom questions, the patients will be provided with an automatic response pushed by the back-end database by crawling the keywords. It is suggested that the answer is just for reference. In case of urgent questions, they will be advised to consult the clinicians.~2. The researchers will communicate with the patients every month.
Study NCT04516265 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: neurodevelopmental treatment
Description: A personally designed treatment program will be applied in line with the principles of neurodevelopmental treatment.
Study NCT04516265 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: video-based trunk training
Description: Games developed for the use of children with cerebral palsy will be used for trunk training.